Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients with purine analogue refractory disease or TP53 dysfunction still have limited treatment options and poor survival. Alemtuzumab containing chemoimmunotherapy regimens can be effective but frequently cause serious infections. We r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Hematol
Main Authors: Zent, Clive S., Taylor, Ronald P., Lindorfer, Margaret A., Beum, Paul V., LaPlant, Betsy, Wu, Wenting, Call, Timothy G., Bowen, Deborah A., Conte, Michael J., Frederick, Lori A., Link, Brian K., Blackwell, Sue E., Veeramani, Suresh, Baig, Nisar A., Viswanatha, David S., Weiner, George J., Witzig, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4280857/
https://ncbi.nlm.nih.gov/pubmed/24723493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23737
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares